Preet M. Chaudhary, MD, PhD

Professor of Medicine

Bloom Family Chair in Lymphoma Research

Chief, Nohl Division of Hematology and Center for Blood Diseases in the Department of Medicine

Director for Bone Marrow Transplant

Image of Preet M. Chaudhary, MD, PhD
Is this your profile? Click to edit

Overview

Preet M. Chaudhary, MD, PhD, is Professor of Medicine at the University of Southern California (USC) in Los Angeles, where he serves as Chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases and holds the Ronald Bloom Family Chair in Lymphoma Research. He is Director of the USC Blood and Marrow Transplant and Cell Therapy Programs.
Dr. Chaudhary’s research focuses on multiple areas of cancer biology and therapeutics, including the development of next-generation chimeric antigen receptor (CAR)-modified T and NK cell therapies. He is an elected member of the American Society for Clinical Investigation and a Senior Member of the National Academy of Inventors.
He has received research fellowships and awards from numerous prestigious organizations, including the March of Dimes, Damon Runyon Cancer Research Foundation (formerly Damon Runyon–Walter Winchell Foundation), Leukemia Research Foundation, Leukemia & Lymphoma Society, Multiple Myeloma Research Foundation, Howard Hughes Medical Institute, National Institutes of Health, U.S. Department of Defense, and the California Institute for Regenerative Medicine. He has been recognized among the “Top Doctors” by Pasadena and Los Angeles magazines.
Under his leadership, the USC Blood and Marrow Transplant Program achieved the highest reported one-year survival rate (>90%) among adult allogeneic transplant programs nationwide. Dr. Chaudhary is an inventor on more than 200 granted and pending patent applications worldwide, including an anticancer patent application that was the most cited in its field globally between 1993 and 2013.

Awards

  • Leukemia Lymphoma Society: Translational Research Award, 2005
     – 2008
  • Leukemia Lymphoma Society: Translational Research Award, 2008
     – 2011
  • Multiple Myeloma Research Foundation: Senior Research Award, 2005
     – 2006
  • American Society for Clinical Investigations, 2004
  • Leukemia Research Foundation: New Investigator Award, 1999
     – 2000
  • Howard Hughes Institutes: New Faculty Start-Up Award, 1998
     – 2001
  • Damon Runyon-Walter Winchell Foundation: Postdoctoral Fellowship, 1995
     – 1998
  • March of Dimes Birth Defects Foundation: Pre-doctoral Fellowship, 1990
     – 1992
  • Second Prize in Ophthalmology, 1986
  • Gold Medal in Surgery, 1986
  • Second Prize in Pathology, 1985
  • Distinctions in Anatomy, Physiology Biochemistry and Pharmacology, 1984
     – 1985
  • Honors in First Professional M.B.B.S, 1984
  • Pre-Medical University Merit Certificate (First Rank in the College), 1981
  • National Talent Search Scholarship, 1981
     – 1986

Research Funding

  • Role of IKK epsilon in KSHV/HHV8 associated malignancies
    NIH · R01DE025804 · Mar 4, 2016 – Feb 28, 2021 · Role: Principal Investigator
  • A High Throughput Protein Complementation Assay for Inhibitors of NEMO-K13 Intera
    NIH · R01CA139119 · Jul 1, 2010 – Jun 30, 2014 · Role: Principal Investigator
  • Cell Penetrating Helical Peptide Inhibitors of vFLIP K13
    NIH · R01DE019811 · Jun 1, 2010 – Mar 31, 2016 · Role: Principal Investigator
  • Small Molecule Inhibitors of K13-Induced NF-kB Activation
    NIH · R21NS063905 · Jun 15, 2008 – May 31, 2010 · Role: Principal Investigator
  • Role of vFLIP K13 in Bone Marrow Failure Syndrome Associated with Infection by Hu
    NIH · R21HL085189 · May 10, 2007 – Oct 30, 2009 · Role: Principal Investigator
  • Role of Arsenic Trioxide in Primary Effusion Lymphoma
    NIH · R01CA124621 · Dec 1, 2006 – Nov 30, 2012 · Role: Principal Investigator
  • Genes in X-linked Ectodermal Dysplasia Receptor
    NIH · R01DE015189 · Apr 1, 2003 – Mar 31, 2008 · Role: Principal Investigator
  • Role of orf-K13, an HHV8 Encoded vFLIP, in the Pathogenesis of AIDS-related Malig
    NIH · R01CA085177 · Jun 1, 2000 – May 31, 2012 · Role: Principal Investigator
  • CASPASE 8 AND ITS HOMOLOGS IN NF-KB AND JNK ACTIVATION
    NIH · R01AI047230 · Apr 1, 2000 – Mar 31, 2006 · Role: Principal Investigator

Publications

  • Correction: BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians. Adv Ther. 2026 Sep 28.. View in PubMed
  • BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians. Adv Ther. 2026 Aug 19.. View in PubMed
  • Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2026 Aug; 26(8):562-573.e1.. View in PubMed
  • Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia. J Med Cases. 2025 Mar; 16(3):102-106.. View in PubMed
  • Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia. J Med Cases. 2024 Oct; 15(10):261-266.. View in PubMed
  • Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy. Br J Haematol. 2024 Dec; 205(6):2234-2247.. View in PubMed
  • Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.. View in PubMed
  • Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study. Leuk Res. 2024 06; 141:107501.. View in PubMed
  • Post-stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib. EJHaem. 2024 Apr; 5(2):423-427.. View in PubMed
  • Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease. Front Oncol. 2024; 14:1329893.. View in PubMed